Sunesis Pharmaceuticals Appoints William L. Schary, Ph.D., Vice President, Regulatory Affairs and Quality Assurance
September 26 2006 - 9:30AM
PR Newswire (US)
Robert McDowell, Ph.D., Promoted to Vice President, Research SOUTH
SAN FRANCISCO, Calif., Sept. 26 /PRNewswire-FirstCall/ -- Sunesis
Pharmaceuticals, Inc. (NASDAQ:SNSS) today announced the appointment
of William L. Schary, Ph.D., to the position of Vice President,
Regulatory Affairs and Quality Assurance. Dr. Schary joins Sunesis
with more than 27 years professional experience in pharmaceutical
product development, regulatory affairs, compliance and quality
assurance. Dr. Schary's career spans various roles in regulatory
affairs and quality assurance for numerous pharmaceutical
companies. Dr. Schary has successfully filed more than 20
registration dossiers in the U.S., Europe, Canada and Asia. He
joins Sunesis from Valeant Pharmaceuticals International, where
from 2003 to present he held the position of Vice President,
Regulatory Affairs. While there, he was responsible for U.S. Food
and Drug Administration (FDA) interactions, participated in
strategic product planning and implemented quality control systems.
Prior to Valeant, Dr. Schary held regulatory and quality positions
at Cellegy Pharmaceuticals, Aronex Pharmaceuticals, Takeda
Pharmaceuticals and CoCensys. He began his career as a reviewer
with the Division of Biopharmaceutics, U.S. Food and Drug
Administration. "I am very pleased to welcome Bill to the Sunesis
team. His extensive background in working with the FDA and with
worldwide regulatory bodies, as well as his strong technical
background in quality assurance, will be invaluable as we advance
our lead programs into late-stage clinical development over the
next year or two," said Daniel Adelman, M.D., Senior Vice President
of Research and Development. The company also announced that Robert
McDowell, Ph.D., who has been serving as the company's Vice
President, Chemistry since 2002, has been promoted to the
newly-created position, Vice President, Research, leading all
early-stage drug discovery and preclinical development efforts. Dr.
Adelman continued, "Bob McDowell has demonstrated excellent
leadership during his tenure with Sunesis. As Vice President,
Research, Bob will play an even greater role in leading all the
non-clinical research efforts at Sunesis, steering our discovery
strategy and informing our clinical development strategies as part
of Sunesis' multidisciplinary approach to successful drug
development." Option Award Disclosure The Compensation Committee of
the company's Board of Directors approved an employment
commencement grant to Dr. Schary of a non-qualified stock option to
purchase 60,000 shares of Sunesis common stock, effective September
29, 2006. This option award was granted without shareholder
approval pursuant to Nasdaq Marketplace Rule 4350 (i)(1)(A)(iv) and
with the following material terms: (a) an exercise price equal to
the fair market value of the company's common stock on the grant
date, (b) a term of ten years, and (c) a vesting schedule providing
that the option is exercisable as to one-quarter of the total grant
on the first anniversary of Dr. Schary's hire, and one-forty-eighth
of the total grant each month thereafter until each grant is fully
vested. About Sunesis Pharmaceuticals Sunesis is a clinical-stage
biopharmaceutical company focused on the discovery, development and
commercialization of novel small molecule therapeutics for oncology
and other serious diseases. Sunesis has built a broad product
candidate portfolio through internal discovery and in-licensing of
novel cancer therapeutics. Sunesis is advancing its product
candidates through in-house research and development efforts and
strategic collaborations with leading pharmaceutical and
biopharmaceutical companies. For additional information on Sunesis
Pharmaceuticals, please visit http://www.sunesis.com/ .
Forward-Looking Statements This press release may contain
forward-looking statements that involve substantial risks and
uncertainties. Sunesis may not actually achieve the plans,
intentions or expectations contained in such forward-looking
statements. Actual results or events could differ materially from
the plans, intentions and expectations contained in such
forward-looking statements. Sunesis does not assume any obligation
to update any such forward-looking statements. DATASOURCE: Sunesis
Pharmaceuticals, Inc. CONTACT: investors, Eric Bjerkholt, CFO,
Sunesis Pharmaceuticals, Inc., +1-650-266-3717; or media, Karen L.
Bergman, +1-650-575-1509, or Michelle Corral, +1-415-794-8662, both
of BCC Partners, for Sunesis Pharmaceuticals, Inc. Web site:
http://www.sunesis.com/
Copyright
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Jul 2023 to Jul 2024